Aristotle University Of Thessaloniki (AUTH)
Μελέτη των μεταβολών της κυτταρικής και της χυμικής ανοσίας σε λήπτες νεφρικού μοσχεύματος μετά από ανοσοποίηση έναντι του ιού SARS-CoV-2 με το εμβόλιο mRNA BNT162b2 (Tozinameran)
Abstract
dc:descriptionIntroduction: Kidney transplant recipients (KTRs) exhibit an impaired immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, with their pre-vaccination immune profile significantly determining immunization efficacy. Furthermore, recent evidence suggests that repeated vaccine doses may influence the differentiation, immune senescence and exhaustion of adaptive immune cells. Methods: Fifty-seven KTRs with no prior SARS-CoV-2 exposure were enrolled. Humoral immunity was assessed by measuring SARS-CoV-2-specific IgG titers against the receptor binding domain (anti-RBD Abs) and neutralizing antibodies (NAbs) using chemiluminescence immunoassay (CLIA). Additionally, flow cytometry was used to analyze alterations in cellular subpopulations (leukocytes, total lymphocytes, B- and T-lymphocyte subsets, NK and NK-T cells, and monocytes). Follow-up lasted 38 weeks, encompassing seven time points (T0-T6, T0: within 48h pre-1st vaccination dose, T1: within 48h pre-2nd dose), T2: 21 days post-2nd dose, T3: within 48h pre-3rd dose, T4: 21 days post-3rd dose, T5: within 48h pre-4th dose and T6: 21 days post-4th dose). This schedule followed the four-dose BNT162b2 regimen (2nd dose: 21 days post-1st, 3rd dose: 120 days post-2nd, 4th dose: 120 days post-3rd). In a subgroup of 39 patients who failed to develop a protective humoral response after the 2nd dose, specific T-cell immunity was further evaluated (using enzyme-linked immunosorbent spot, ELISpot), alongside markers of immunosenescence and exhaustion. These patients were classified as “responders” or “non-responders” based on the presence of adequate NAb titers and/or a positive ELISpot test result. Results: A four-dose vaccine regimen was required to achieve satisfactory anti-RBD Ab and NAb titers in nearly all of the 57 patients (94,74% and 85,96%, respectively). Patients who developed antibodies had a higher initial estimated glomerular filtration rate (eGFR) value and a shorter pre-transplantation dialysis vintage.We observed a significant increase in the concentrations of memory B-cells (p: 0,028) and activated helper T-cells (p: 0,005), while exhausted T-lymphocytes (p < 0,001) and NK cells (p: 0,011) decreased (time points: T0 vs. T2 vs. T3). Moreover, 41% of the patients without NAbs 120 days after the 2nd dose (T3), had already developed virus-specific protective T-cell immunity. At baseline (T0), “responders at T4” presented significantly higher concentrations of total B-lymphocytes [97(93)/μL vs. 51(52)/μL, p: 0,045] and transitional B-cells [9(17)/μL vs. 1(2)/μL, p: 0,031] compared to “non-responders”. In the same patient group, during the T0-T3 interval, an increase in activated helper [7(4)/μL vs. 10(11)/μL, p: 0,001] and cytotoxic [8(19)/μL vs. 15(16)/μL, p: 0,004] T-lymphocytes was noted, alongside a concurrent reduction of exhausted T-cell subsets [130(121)/μL vs. 30(25)/μL, p: 0,001]. Proportionally, there was a rise in memory B-cells, marginal zone B-cells, and NK T-cells, while naïve B-cells declined. During the T3-T4 interval, transitional B-lymphocyte concentrations [1(3)/μL vs. 18(21)/μL, p: 0,003] and the proportion of total CD8+ T-cells increased, whereas activated CD4+ T-cells dropped, both in absolute counts [10(11)/μL vs. 5(5)/μL, p: 0,042] and percentages, as did the proportion of NK T-cells. Within the subgroup of 39 patients, the transition from T3 to T4 was characterized by an increase in effector memory CD8+ T-cells [CD8+ TEM: 27(26)/μL vs. 44(49)/μL, p: 0,010] and in the proportion of central memory CD4+ T-cells (CD4+ TCM), alongside a reduction of naïve CD4+ and CD8+ T-cell subsets. In contrast, exhausted T-lymphocytes remained stable. Finally, at T4, “responders” presented lower counts of CD4+CD28- cells [63(54)/μL vs. 161(92)/μL, p: 0,026] and higher concentrations of CD8+CD28+ cells [227(147)/μL vs. 131(121)/μL, p: 0,036] compared to “non-responders”. Conclusions: The development of SARS-CoV-2-specific T-cell responses precedes that of humoral immunity. “Responders” and “non-responders” (following the 3rd dose) differ significantly in their baseline immune profiles and their cellular subpopulation dynamics during follow-up. Finally, successful immunization was not connected to an increase in senescent or exhausted T-cells, but rather to a clear shift from naïve subsets toward more differentiated and activated T-cell subpopulations.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Stai, Stamatia
- Στάη, Σταματία
Subjects
dc:subject × 29- Λήπτης νεφρικού μοσχεύματος
- SARS-CoV-2
- Εμβολιασμός
- BNT162b2
- Ανοσιακό σύστημα
- Χυμική απόκριση
- Κυτταρική απόκριση
- ELISpot
- Ανοσολογική γήρανση
- Ανοσολογική εξάντληση
- Kidney transplant recipient
- Vaccination
- Immune system
- Humoral response
- Cellular response
- Immunosenescence
- Immunoexhaustion
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Νεφρολογία
- Μεταμοσχεύσεις
- Βασική Ιατρική
- Ανοσολογία
- Clinical Medicine
- Medical and Health Sciences
- Nephrology
- Transplantation
- Basic Medicine
- Immunology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61918